| 000 | 00625nam a22002052 4500 | ||
|---|---|---|---|
| 001 | hsl001006001 | ||
| 003 | DGPO | ||
| 005 | 20170826152548.0 | ||
| 008 | 170110s1974 dcu f000 0 eng d | ||
| 040 |
_aGPO _cGPO _dMvI |
||
| 086 | 0 | _aHE 20.3161/A:C 16/3 | |
| 099 | _aHE 20.3161/A:C 16/3 | ||
| 245 | 0 | 0 | _aBiochemical characterization of cancer immunotherapeutic agent-MSF-MB. |
| 260 |
_a[Washington, D.C., _c1974] |
||
| 300 | _av. | ||
| 500 | _aReprinted from vol.53, no.1, July 1974. | ||
| 500 | _aCRDP Program Historic Shelflist record. | ||
| 650 | 0 |
_aCancer _xResearch. |
|
| 710 | 2 | _aNational Cancer Institute (U.S.) | |
| 949 |
_aBEV _bFed Docs |
||
| 999 |
_c264188 _d264188 |
||